2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156027
    SIRT6-IN-3 3023471-40-8 98.19%
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.
    SIRT6-IN-3
  • HY-156532
    5-HT2C agonist-3 2104810-18-4 99.86%
    5-HT2C agonist-3 ((+)-19) is a selective 5-HT2C agonist (EC50: 24 nM, Ki: 78 nM). 5-HT2C agonist-3 has antipsychotic drug-like activity. 5-HT2C agonist-3 blocks Amphetamine-induced hyperactivity.
    5-HT2C agonist-3
  • HY-156596
    Aneratrigine 2097163-74-9 99.60%
    Aneratrigine is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine can be used for neuropathic pain diseases research.
    Aneratrigine
  • HY-156666
    Casein kinase 1δ-IN-8 851396-73-1 ≥98.0%
    Casein kinase 1δ-IN-8 (compound 494) is an inhibitor of Casein kinase 1δ, Casein kinase 1δ-IN-8 can be used in the treatment of neurodegenerative disorders such as Alzheimer's disease[1].
    Casein kinase 1δ-IN-8
  • HY-156842
    MCAAD-3 1625629-51-7
    MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice.
    MCAAD-3
  • HY-15720B
    Glycyl H-1152 hydrochloride 913844-45-8 98%
    Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and PKG, with IC50s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride.
    Glycyl H-1152 hydrochloride
  • HY-157343
    GD3 Ganglioside 62010-37-1 98%
    GD3 Ganglioside is a prominent ganglioside of human melanoma. GD3 Ganglioside is an inducer of mitochondrial permeability. GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion. GD3 ganglioside is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis.
    GD3 Ganglioside
  • HY-157549
    Brivoligide 1803075-42-4 98%
    Brivoligide (AYX1) is a double-stranded, unprotected, 23 base-pair oligonucleotide. Brivoligide can reduce acute post-surgical pain. Brivoligide mimics the DNA sequence normally bound by EGR1 on chromosomes.
    Brivoligide
  • HY-157727
    HDHD4-IN-1 1447279-68-6 99.20%
    HDHD4-IN-1 (compound 3) is a N-acetylneuraminate-9-phosphate phosphatase (HDHD4) inhibitor (IC50=11 μM). HDHD4-IN-1 can be used in the study of neurological diseases.
    HDHD4-IN-1
  • HY-157999
    SDI-118 1651179-19-9 98.86%
    SDI-118 is an orally active modulator for synaptic vesicle glycoprotein 2A (SV2A) with an IC50 of 13 nM.
    SDI-118
  • HY-158204
    CNB-001 1019110-87-2 98%
    CNB-001 is a potent 5-lipoxygenase (5-LOX) inhibitor, decreases 5-LOX expression, and increases proteasome activity. CNB-001 also increases eIF2α phosphorylation and HSP90 and ATF4 levels in Alzheimer's disease transgenic mice, and limits the accumulation of soluble Aβ and ubiquitinated aggregated proteins. CNB-001 maintains the expression of synapse-associated proteins and improves memory. CNB-001 can be used for the research of Alzheimer's disease.
    CNB-001
  • HY-159109
    HDAC6-IN-46 3038789-39-5 98.51%
    HDAC6-IN-46 (compound 12) is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 value of 6.2 nM. HDAC6-IN-46 can be used in Alzheimer's disease research.
    HDAC6-IN-46
  • HY-159113
    PCC0105003 99.88%
    PCC0105003 is a potent MARK inhibitor. PCC0105003 can be used in the study of neuropathic pain.
    PCC0105003
  • HY-159639
    BAY-2925976 2642235-06-9 99.14%
    BAY-2925976 is an α2C adrenergic receptor (ARα2C) antagonist that can be used for the study of obstructive sleep apnea (OSA).
    BAY-2925976
  • HY-159835
    Oveporexton 2460722-04-5 98%
    Oveporexton (TAK-861) is an orally active and selective OX2R agonist with an EC50 of 2.5 nM. Oveporexton ameliorates narcolepsy-like phenotypes.
    Oveporexton
  • HY-159836
    Nivegacetor 2443487-67-8 98%
    Nivegacetor is a potent γ-secretase modulator.
    Nivegacetor
  • HY-15997C
    (±)-U-50488 hydrate hydrochloride 99.76%
    (±)-U-50488 ((±)-Trans-(1R,2R)-U-50488) hydrate hydrochloride is a selective κ opioid receptor (KOR) agonist.
    (±)-U-50488 hydrate hydrochloride
  • HY-160115
    TDP-43 degrader-1 2902692-25-3
    TDP-43 degrader-1 (example 3) reduces the TDP-43 aggregation that can be in the research of Amyotrophic lateral sclerosis and? Alzheimer's disease.
    TDP-43 degrader-1
  • HY-160426
    Gcase activator 3 2270984-21-7 99.67%
    Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies.
    Gcase activator 3
  • HY-160887
    FPT 2048491-06-9 98.06%
    FPT, a 2-Aminotetralin, is an efficacious partial agonist at 5-HT1AR, a full agonist at 5-HT1BR and 5-HT1DR with EC50s of 39.3 nM, 1.2 nM, 0.5 nM, respectively. FPT is a weak agonist at 5-HT7R. FPT shows in vivo efficacy as an antiepileptic in Fmr1 knockout mice and has anxiolytic-like and prosocial effects in Fmr1 knockout mice and other mouse models.
    FPT
Cat. No. Product Name / Synonyms Application Reactivity